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Somatic Mutations in MAP3K5 Attenuate Its
Proapoptotic Function in Melanoma through
Increased Binding to Thioredoxin
Todd D. Prickett1,13, Brad Zerlanko1,13, Jared J. Gartner1, Stephen C.J. Parker1, Ken Dutton-Regester2,
Jimmy C. Lin3, Jamie K. Teer4,14, Xiaomu Wei1, Jiji Jiang1, NISC Comparative Sequencing Program5,
Guo Chen6,7, Michael A. Davies6,7, Jeffrey E. Gershenwald8,9, William Robinson10, Steven Robinson10,
Nicholas K. Hayward2, Steven A. Rosenberg11, Elliott H. Margulies12,15 and Yardena Samuels1,16
Patients with advanced metastatic melanoma have poor prognosis and the genetics underlying its pathogenesis
are poorly understood. High-throughput sequencing has allowed comprehensive discovery of somatic mutations
in cancer samples. Here, on analysis of our whole-genome and whole-exome sequencing data of 29 melanoma
samples, we identified several genes that harbor recurrent nonsynonymous mutations. These included MAP3K5
(mitogen-activated protein kinase kinase kinase-5), which in a prevalence screen of 288 melanomas was found to
harbor a R256C substitution in 5 cases. All MAP3K5-mutated samples were wild type for BRAF, suggesting a mutual
exclusivity for these mutations. Functional analysis of the MAP3K5 R256C mutation revealed attenuation of MKK4
(mitogen-activated protein kinase kinase 4) activation through increased binding of the inhibitory protein
thioredoxin (TXN/TRX-1/Trx), resulting in increased proliferation and anchorage-independent growth of mela-
noma cells. This mutation represents a potential target for the design of new therapies to treat melanoma.
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INTRODUCTION
In the United States, one in four deaths occurs as a result of
cancer. Despite this striking statistic, overall death rates are
decreasing, largely because of improved diagnosis and treat-
ment strategies for a subset of patients. Even with these
improvements, there are still a number of cancers whose
incidence rates continue to rise. Melanoma falls within this
category; in the United States alone,B76,690 new diagnoses
and 9,480 deaths are predicted for 2013 (Siegel et al., 2012,
2013). For these reasons, further understanding of the
molecular pathogenesis of this potentially lethal disease is
needed.
The development and progression of melanoma can be attri-
buted to the acquisition of somatic aberrations. Targeting these
mutations through use of molecularly based targeted drugs has
recently led to significant clinical responses in metastatic mela-
noma, such as the use of vemurafenib or dabrafenib in BRAF-
mutant tumors (Flaherty et al., 2010; Chapman et al., 2011).
However, despite the success in identifying genetic alterations
utilizing candidate gene approaches (Davies et al., 2002; Curtin
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et al., 2006; Prickett et al., 2009) as well as whole-genome
(Pleasance et al., 2010; Turajlic et al., 2011; Berger et al., 2012)
and whole-exome (Wei et al., 2011; Krauthammer et al., 2012;
Nikolaev et al., 2012; Stark et al., 2012) sequencing, there
remain a significant number of patients with advanced
melanoma without a targetable mutation. Further identification
of alterations in new genes represents an ongoing urgent need.
Mitogen-activated protein kinase (MAPK) pathway regulates
cellular processes such as proliferation, survival, and migra-
tion (Robinson and Cobb, 1997). Further potentiation of these
signaling molecules through either amplification or somatic
mutations play a major role in tumorigenesis (Dicker et al.,
1990; Davies et al., 2002; Nikolaev et al., 2011; Stark et al.,
2011) and large-scale cancer genetic studies support these
findings (Dicker et al., 1990; Davies et al., 2002; Clark et al.,
2004; Marks et al., 2008; Johannessen et al., 2010; Nikolaev
et al., 2011; Stark et al., 2012). Recently, large-scale genetic
studies of melanoma found the MAPK family members
MAP2K1 (MEK1) and MAP2K2 (MEK2) to harbor recurrent
somatic mutations, leading to increased signal transduction,
proliferation, and cellular transformation, suggesting that
further investigation of mutational activation of the MAPK
pathway in melanoma is warranted (Marks et al., 2008;
Nikolaev et al., 2011).
The MAP3K5 (mitogen-activated protein kinase kinase
kinase-5), also known as apoptosis signal-regulating kinase 1
(ASK1), is a serine/threonine protein kinase that activates c-Jun
N-terminal kinase and p38 (Yang et al., 2010; Tzeng et al.,
2013) via activation of MAPK kinase-4/7 (MKK4/7). MAP3K5
can be activated in response to stress signals, including H2O2,
tumor necrosis factor-a, or reduced serum levels (Tzeng et al.,
2013). It has been shown that a molecular target of reactive
oxygen species (ROS), thioredoxin (TXN/Trx), is an inhibitor of
MAP3K5 (Saitoh et al., 1998). Trx binds to the N-terminus of
MAP3K5, attenuating its kinase activity as well as downstream
apoptotic signaling mechanisms (Saitoh et al., 1998). Oxidation
via ROS disrupts binding of Trx to MAP3K5, resulting in
apoptosis. Interestingly, normal melanocytes are known to
scavenge ROS, whereas melanoma cells contain structurally
abnormal melanocytes that generate free radicals (Fruehauf and
Trapp, 2008; Gidanian et al., 2008). As a result, a mutation in
MAP3K5 in melanoma cells that strengthens the interaction
with Trx could lead to evasion of cell death and thus increased
survival in the face of excessive amounts of ROS.
Here we analyzed whole-genome and whole-exome data to
identify recurrent somatically mutated genes in melanoma.
One of the most interesting findings in this study was that
the gene encoding MAP3K5 harbored a recurrent somatic
mutation (R256C) in 5/288 tumors that was found to be
mutually exclusive with BRAF mutations. Through functional
analysis we demonstrated the importance of this mutation on
MAP3K5 activity, by reducing the protein’s prodeath activity
and increasing melanoma cell survival.
RESULTS AND DISCUSSION
Genetic analysis reveals a hotspot mutation in MAP3K5 (R256C)
Recent sequencing projects using Sanger/whole-exome/
whole-genome techniques have implicated many different
genes involved in melanomagenesis (Pleasance et al., 2010;
Turajlic et al., 2011; Wei et al., 2011; Berger et al., 2012;
Hodis et al., 2012; Krauthammer et al., 2012; Nikolaev et al.,
2012; Stark et al., 2012). To further our understanding of the
molecular changes that underlie melanoma, and to identify
potential drug targets, we searched our sequencing data for
recurrent mutations in genes that are permeable to small-
molecule inhibition such as serine/threonine kinases.
We comprehensively analyzed the coding regions of
29 melanoma samples and corresponding normal DNA. To
search for recurrent mutations, we looked for alterations that
occurred in two or more of the 29 samples subjected to
whole-exome/whole-genome sequencing reanalysis. From this
analysis we identified the previously described BRAF (V600E)
alteration in 16 out of the 29 samples and the TRRAP (S722F)
substitution (Davies et al., 2002; Wei et al., 2011). We found
two samples with the same mutation in MAP3K5, and given
the recent report by Stark et al. (2012), indicating the potential
importance of this gene in melanoma development, we
focused our follow-up work on MAP3K5.
Screening for the R256C alteration in MAP3K5 in an
additional 172 melanomas identified an additional four cases
with the mutation—cytosine-to-thymine change at position
766 of the transcript (NM_005923.3)—leading to arginine-to-
cysteine substitution at amino acid residue 256 of the protein
(R256C) (Supplementary Figure S1 online). Furthermore,
sequencing of the MAP3K5 recurrent mutation in an indepen-
dent cohort of 87 melanomas yielded a fifth sample with
the same mutation (Supplementary Table S1 online). An
additional interrogation of data from two recently published
melanoma exome studies identified numerous mutations
occurring in MAP3K5 (Hodis et al., 2012; Krauthammer
et al., 2012) (Supplementary Table S2 online contains a list
of mutations occurring in MAP3K5 from whole-exome and
genome sequenced samples screened or reanalyzed in this
study). In these data sets, the MAP3K5 hotspot mutation
occurred in 2/121 cases or 0/147 cases, respectively.
The probability for the occurrence of this recurrent alteration
is significantly low (Po3.14E 13; binomial distribution
followed with Bonferroni correction (Po1.57E5)) and the
affected residue is highly conserved (Supplementary Figure S2
online), suggesting that it has been selected for during tumor
development.
In order to fully assess the mutual exclusivity with our
recurrent mutation and BRAF, we reviewed two published
exome studies (Hodis et al., 2012; Krauthammer et al., 2012)
as well as TCGA (The Cancer Genome Atlas) cutaneous
melanoma exome data publically available at https://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm. As our study
focused exclusively on cutaneous malignant melanoma, we
removed all uveal, acral, and mucosal melanoma samples
from the published exome studies. This analysis left us with
435 exome samples to review, and revealed 4 samples to
contain the recurrent p.R256C. Of these 435 samples, 215
contained the BRAF p.V600E mutation and only a single
sample contained both the recurrent MAP3K5 mutation and
the recurrent BRAF mutation. When these studies are
combined with our samples, we then have 723 total
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samples assessed for these two positions, with 9 containing the
recurrent MAP3K5 mutation, 366 containing the recurrent
BRAF mutation, and a single sample containing both
mutations. Using the combination of additional exome data
and our samples a Fisher’s exact test indicates an almost
mutual exclusivity between the MAP3K5 recurrent mutation
and BRAF V600E (P-value¼0.01016; see Supplementary
Figure S3 online). Because of the frequency of the MAP3K5
R256C mutation in melanoma, we decided to investigate
whether the mutation has a role in tumorigenesis.
Expression of MAP3K5 (R256C) in melanoma cells leads to
suppression of proapoptotic signaling and increased anchorage-
independent growth
MAP3K5 is stimulated via inflammatory cytokines (tumor
necrosis factor-a, lipopolysaccharide, or IL-6), reactive oxygen
species (H2O2), or UV light via direct activation of its
upstream cognate receptors (Hattori et al., 2009). Upon
activation, MAP3K5 stimulates the stress-induced MAPKs
c-Jun N-terminal kinase and/or p38 via MKK4/7, leading to
an increased propensity for cell death or apoptosis. A marker
of MAP3K5 proapoptotic effect is the measure of the
phosphorylation state of MAP3K5 (Hattori et al., 2009).
Phosphorylation of MAP3K5 on Thr845, a critical residue in
the activation loop, is required for its activation of pro-
apoptotic signaling (Tobiume et al., 2002). To test the effects
of mutant MAP3K5 on its activity as well as its downstream
substrates, we transiently expressed vector control, wild-type
or mutant (R256C) MAP3K5 in HEK293T cells as well as
established stable pooled clones expressing the same
constructs in Mel-STR or 2183 (17T) melanoma cells that
are wild-type BRAF but express mutant NRAS similar to what
was observed in our genetic screen. We observed similar
levels of expression of MAP3K5 protein in both the HEK293T,
Mel-STR, and 2183 (17T) cells. We tested for MAP3K5 activa-
tion by using site-specific phospho-antibodies to MAP3K5.
Expression of mutant MAP3K5 (R256C) in HEK293T, Mel-STR,
or 2813 cells resulted in phosphorylation of Thr845 in the
MAP3K5 activation loop being suppressed compared with
cells expressing wild-type MAP3K5 (Figure 1a–c). As seen
in Figure 1, phospho-MKK4 and phospho-p38 signals are
reduced in the mutant MAP3K5 compared with the wild
type in both the transient expression and stably expressed
pooled clones. These results suggest that somatic mutation of
MAP3K5 (R256C) may cause melanoma cells expressing
mutant MAP3K5 (R256C) to evade MAP3K5-dependent
stress-induced cell death signals by suppressing its proapop-
totic activity.
To examine the effects of MAP3K5 mutation on cell growth,
we tested Mel-STR or 2183 (17T) stable pooled clones expres-
sing vector control, wild-type, or mutant (R256C) MAP3K5 for
anchorage-independent growth or growth on plastic.
We selected the melanoma cell lines Mel-STR and 2183
(17T), as they both express wild-type MAP3K5 and are wild
type for BRAF. When assessing growth in soft agar, Mel-STR
and 2183 (17T) clones expressing wild-type MAP3K5 showed
reduced colony formation compared with mutant MAP3K5
(R256C) or empty vector (Figure 2a and b). We next examined
growth on plastic and found that in the presence of normal
serum levels (10%), both Mel-STR and 2183 (17T) pooled
clones expressing MAP3K5 wild-type or R256C exhibited
similar proliferation rates (Supplementary Figure S4A and B
online). However, although Mel-STR pooled clones expressing
wild-type or R256C in the presence of low serum (1%) also
exhibited similar proliferation rates (Figure 2c), the 2183 (17T)
pooled clones expressing R256C exhibited elevated prolifera-
tion rates compared with wild-type expressing cells (Figure 2d).
These data suggest that expression of wild-type MAP3K5 may
induce a proapoptotic signal in melanoma cells resulting in
reduced anchorage-independent growth and proliferation.
MAP3K5 acts as a tumor suppressor in melanoma cells as
determined by stable shRNA depletion
To determine whether melanoma cells with endogenous
MAP3K5 mutations are dependent on MAP3K5 signaling for
proliferation, we used small hairpin RNA (shRNA) to stably
knock down MAP3K5 in melanoma cells harboring either
wild-type MAP3K5 (501Mel and 12T) or mutant MAP3K5 (32T
and Mel-Juso). Specific targeting of MAP3K5 was confirmed
by transient transfection in HEK293T cells (Figure 3a) and
immunoblotting as well as reverse transcription–PCR analysis,
using MAP3K5-specific primers and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as a loading control
(Figure 3b). The shRNA had little to no effect on cells
harboring wild-type MAP3K5 but significantly reduced the
growth of cells harboring mutant forms of MAP3K5
(Figure 3c). Taken together, our results demonstrate that the
recurrent somatic mutation of MAP3K5 is essential for cellular
proliferation and anchorage-independent growth, a pheno-
typic hallmark of invasive malignant melanoma cells.
Attenuation of MAP3K5 proapoptotic phenotype by increased
binding of Trx to mutant MAP3K5 (R256C)
Finally, to determine the mechanism responsible for attenua-
tion of MAP3K5-induced apoptosis by the R256C mutation,
we tested the ability of transiently expressed or stably
expressed wild-type or mutant (R256C) to bind the MAP3K5
inhibitor thioredoxin (TXN/Trx) in HEK293 or 2183 (17T) cells,
respectively. As seen in Figure 4, wild-type MAP3K5-FLAG
binds transiently expressed myc-Trx (Figure 4a) or endogenous
Trx (Figure 4b). However, mutant MAP3K5-FLAG binds myc-
Trx or Trx significantly better in both the transient system and
stable pooled clones. These results suggest a potential mecha-
nism for how cancer cells harboring the R256C MAP3K5
mutation are able to avert apoptosis, leading to progression of
melanoma tumorigenesis.
Here we report the identification of a recurrent somatic
mutation in MAP3K5 at R256C that is predominately mutually
exclusive to BRAF mutation. Functional analysis revealed that
transient expression of the mutant form of MAP3K5 caused an
attenuation of the prodeath pathways of p38 or c-Jun N-term-
inal kinase. Furthermore, mutation of MAP3K5 resulted in
increased proliferation as well as anchorage-independent
growth, further demonstrating attenuation of the prodeath
MKK4/7 signaling pathway causing increased survival via
MEK/MAPK activation.
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Components of the MAPK pathway including BRAF and
NRAS have been reported previously to be mutated in
melanoma and lead to phenotypes similar to the ones
described above (Dicker et al., 1990; Davies et al., 2002).
Recent genetic studies of MEK1 and/or MEK2 found them both
to harbor recurrent somatic mutations resulting in increased
MAPK1/2 (extracellular signal–regulated kinase1/2 (Erk1/2))
activation, proliferation, and cellular transformation (Marks
et al., 2008; Nikolaev et al., 2011). Interestingly, hyper-
activated forms of these kinases have increased sensitivity to
inhibition using small-molecule inhibitors targeting the MAPK
pathway, including PLX4032 (vemurafenib) (Bollag et al.,
2010; Flaherty et al., 2010; Halaban et al., 2010; Chapman
et al., 2011). However, responses to these targeted drugs are
often short lived, with resistance occurring through a variety of
mechanisms including the acquisition of secondary somatic
mutation events or utilization of different RAF isoforms (Alcala
and Flaherty, 2012). Thus, there is a strong need to identify
additional inhibitors as well as drug targets.
Recently, an exome sequencing analysis of melanoma cell
lines identified gene-wide nonsynonymous somatic mutations
of MAP3K5 in 8 of 85 melanomas (Stark et al., 2012). How-
ever, in contrast to this study, the MAP3K5 mutations analyzed
had little to no effect on downstream activation or suppression
of c-Jun N-terminal kinase or p38, nor did we observe a nega-
tive effect on the MEK/MAPK pathway for the MAP3K5 R256C
mutation. These differences may be accounted for by the loca-
tion of the mutated residues throughout the protein analyzed
in the respective studies; whereas the R256C mutation lies
close to the N-terminal region of the protein, the mutations
previously investigated are located centrally near the kinase
domain (amino acids E663 and I780) (Supplementary Figure
S5 online). Recent work by Kim et al. (2012) demonstrated that
the N- and C-terminal regions of the MAP3K5 (ASK1) protein
are important for binding to the transforming growth factor-b–
activated kinase 1 (TAK1)–TAK1 binding protein 1 (TAB1)
complex. This complex formation negatively regulates
MAP3K5 activity, thus attenuating the proapoptotic signal.
The mid-region of MAP3K5, amino acid residues 278–945,
did not associate with the TAK1–TAB1 complex and thus
could not be negatively regulated. The importance of the N-
and C-terminal regions compared with the mid-regions of
MAP3K5 demonstrates the complexity of this kinase, and may
explain the differences observed in pathway stimulation.
Prodeath signaling pathways can be activated via many
different stimuli such as tumor necrosis factor-a, H2O2, Fas
ligand, or reduced serum levels ( Liu et al., 2000; Liu and Min,
2002; Shiizaki et al., 2013). On activation of death receptors
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Figure 1. Effects of the mitogen-activated protein kinase kinase kinase-5 (MAP3K5; R256C) recurrent mutation on cell signaling. Lysates and immunoprecipitates
from cells transiently or stably expressing wild-type or mutant MAP3K5 were analyzed for activation of MAP3K5 and its downstream effector molecules.
(a) HEK293T cells were transiently transfected with wild-type MAP3K5 (WT) or mutant MAP3K5 (R256C) or empty vector as control. Lysates were generated
and immunoblotted with the indicated antibodies. (b) Mel-STR and (c) 2183 (17T) stably expressing MAP3K5 (WT, R256C, or empty vector) clones were
tested for increasing signaling downstream of MAP3K5. Lysates were immunoprecipitated with anti-FLAG (M2) beads or directly analyzed via SDS-PAGE.
Immunoblots were probed with the indicated antibodies. In each case, anti-GAPDH was used as a loading control. ASK1, apoptosis signal-regulating kinase 1;
ERK1/2, extracellular signal–regulated kinase1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IP, immunoprecipitation; MEK, MAPK/ERK kinase;
MKK4, mitogen-activated protein kinase kinase 4; WT, wild type.
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by these ligands, proapoptotic signals involving, e.g., the
tumor necrosis factor receptor or ROS, cause increased poten-
tiation of stress-induced MAPK signaling, resulting in program-
med cell death (Tonissen and Di Trapani, 2009). MAP3K5,
under normal conditions, can be activated by loss of binding
complex formation with its cytoplasmic inhibitor, thioredoxin
(TXN/Trx) (Saitoh et al., 1998). Trx binds the N-terminal region
of MAP3K5, causing inhibition of the proapoptotic kinase.
The binding between these molecules utilizes two highly
conserved cysteine residues in Trx (Cys32 and Cys35)
(Mahmood et al., 2013). Trx inhibits MAP3K5-mediated apop-
tosis after reduction of Cys32 and Cys35, resulting in
increased binding. The fact that we observed increased bind-
ing of Trx to the MAP3K5 R256C compared with wild-type
MAP3K5 suggests a way for evasion of programmed cell
death signals that induce apoptosis. Inhibition of apoptosis
via this mechanism would result in a more proliferative and
prosurvival pathway being upregulated, increasing the
probability of tumorigenesis and/or metastases.
Our study of melanoma genomes and exomes identified a
recurrently mutated gene that is mutually exclusive with
BRAF. We provide functional evidence that the MAP3K5
hotspot mutation is an inactivating event that leads to the
evasion of apoptotic pathways and promotes the colony-
forming abilities of melanoma cells, thus providing a potential
therapeutic target for the population of patients who are
unresponsive to therapies that target BRAF. Although addi-
tional studies will be required to translate our findings to the
clinic, our data point to subpopulations of individuals whose
tumors are dependent on MAPK signaling, thus further
emphasizing the importance of targeting this pathway in
melanoma patients (Romano et al., 2011).
MATERIALS AND METHODS
Tumor tissues
Tissue and melanoma cell lines used for the discovery and pre-
valence screen in this study have been described previously (Palavalli
et al., 2009). All specimens are from an institutional review board–
approved study and written informed consents have been obtained for
all specimens. The Office of Human Subjects Research determined
that Federal regulations for the protection of human subjects
approved this study. All metastatic melanoma samples and peripheral
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Figure 2. Effects of the mitogen-activated protein kinase kinase kinase-5 (MAP3K5; R256C) recurrent mutation on cell growth and proliferation. (a) Wild-type
MAP3K5 suppresses growth in soft agar. Mel-STR and 2183 (17T) pooled MAP3K5 clones were seeded into soft agar to test for anchorage-independent
growth. Mel-STR (WT, R256C, or empty vector) clones were grown for 10 days before harvesting, staining, and counting. (b) 2183 (17T) (WT, R256C, or empty
vector) clones were grown for 10 days before harvesting, staining, and counting. NIH ImageJ and Microsoft Excel were used to analyze experiments.
Mel-STR or 2183 (17T) pooled clones were seeded in 96-well plates in various serum concentrations to assess for differences in growth properties on cells
expressing either WT MAP3K5 or R256C. (c) Mel-STR (WT, R256C, or empty vector) clones were seeded in 96-well plates in the presence of 1% serum and
grown for 9–14 days. SYBR Green was used to determine cell counts per day harvested. (d) 2183 (17T) (WT, R256C or empty vector) clones were seeded
in 96-well plates in the presence of 1% serum and grown for 9–14 days. SYBR Green was used to determine cell counts per day harvested. NIH ImageJ
and Microsoft Excel were used to analyze experiments. Graphs are averages of three parallel experiments with s.d. (n¼3; *comparing WT or R256C with
empty vector, ***comparing WT R256C to empty vector); *Po0.05 and ***Po0.0001 using an unpaired Student’s t-test).
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blood collected and sequenced in this study were done under
protocols approved by the Institutional Review Board of National
Institutes of Health-National Cancer Institute. The Declaration of
Helsinki Principles were followed and patients gave their written
informed consent before enrollment and sample collection. Tissues
used for Validation set 1 were fresh frozen melanoma tumors
obtained from the University of Colorado Denver Skin Cancer
Biorepository, Division of Medical Oncology (Denver, CO). Tissue
was collected at the University of Colorado Hospital, Anschutz
Medical Campus (Aurora, CO), under institutional review board
protocols. DNA was isolated from enriched macrodissected tumor
isolates as previously described (http://www.riedlab.nci.nih.gov).
Tissue processing and storage was previously described by Morente
et al. (2006). Tissues used for Validation set 2 of melanomas were
obtained from optimum cutting temperature–embedded frozen clin-
ical specimens from the Melanoma Informatics, Tissue Resource, and
Pathology Core (MelCore) at The University of Texas MD Anderson
Cancer Center (Houston, TX) under institutional review board–
approved protocols. DNA isolation from the tumor-enriched isolates
has been described previously (Davies et al., 2009). Additional tissue
was collected and cell lines established at Queensland Institute of
Medical Research (Brisbane, QLD, Australia; 41 stage III and 46 stage
IV (AJCC) early-passage metastatic melanoma cell lines). All cell lines
were established as described previously (Castellano et al., 1997;
Pavey et al., 2004; Dutton-Regester et al., 2012) with informed
patient consent under a protocol approved by the human research
ethics committee of the Queensland Institute of Medical Research.
PCR, sequencing, andMAP3K5 mutational analysis of melanoma
samples
The MAP3K5 recurrent mutation was confirmed and further
screened using primers listed in Supplementary Table S3 online in
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Figure 3. Effects of stable depletion of mitogen-activated protein kinase kinase kinase-5 (MAP3K5) on melanoma cell growth. The small hairpin RNA
(shRNA)–mediated depletion of MAP3K5 was tested using transient transfection and immunoblotting of lysates or reverse transcription–PCR (RT–PCR) analysis
of mRNA from melanoma cells depleted of endogenous MAP3K5. (a) Lysates from HEK293T transiently transfected with MAP3K5-FLAG and either one of
three MAP3K5-specific shRNAs or empty vector were immunoblotted using the indicated antibodies to show specificity. (b) mRNA from the 501Mel melanoma
cell line was tested for stable depletion of MAP3K5 using RT–PCR analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading
control. (c) Depletion of MAP3K5 decreases proliferation of melanoma cells with mutant MAP3K5. Melanoma cells harboring either wild-type (WT) or
mutant MAP3K5 were depleted of MAP3K5 and seeded in 96-well plates to assess for differences in growth properties. The cells were harvested and tested
for proliferation using SYBR Green I. Microsoft Excel was used to analyze experiments and generate graphs that are averages of three parallel experiments
with s.d. (n¼3).
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an additional 172 melanoma samples. Mutational analysis, confirma-
tion, and determination of somatic status were carried out as
previously described (Palavalli et al., 2009; Prickett et al., 2009).
Statistical calculation of the likelihood of a recurrent mutation
The probability of a specific base mutated at 5/288 is calculated using
the binomial distribution assuming a background mutation rate of
28.8 mut/Mb (dipyrimidine mutation rate) employing the following
values and formula:
x¼ 5, n¼ 288, P¼ 28.8e 6.
F ðx;n;pÞ ¼ PrðXpxÞ ¼
Xxb c
i¼0
n
i
 
pið1 pÞn i
This is then corrected for multiple comparisons to arrive at the
probability of any base mutated at 5/288 in the study by using a
conservative Bonferroni correction such that the number is multiplied
by the number of coding bases sequenced.
Construction of wild-type and mutant expression vectors
Human MAP3K5 (NM_005923.3) were cloned by PCR as previously
described (Palavalli et al., 2009) using clones (6007002-MAP3K5)
purchased from Open Biosystems (Huntsville, AL) with primers listed
in Supplementary Table S4 online. The PCR products were cloned
into the mammalian expression vectors pCDF-MCS2-EF1-Puro or
pCDF-MCS2-EF1-Neo (Systems Biosciences, Mountain View, CA) or
pcDNA3.1( ) (Invitrogen-Life Technologies, Grand Island, NY) via
the XbaI and NotI restriction sites. MAP3K5 complementary DNA
contains a FLAG epitope tag in-frame at the C-terminus. Point
mutations were introduced as previously described methods
(Prickett et al., 2009) using the primers found in Supplementary
Table S4 online. Thioredoxin (myc-Trx) wild type was purchased from
Addgene (Cambridge, MA) (Plasmid 21614).
Cell culture and transient expression
HEK293 and HEK293T cells were purchased from ATCC (Manassas,
VA) and maintained in complete RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS). HEK293 and HEK293T cells were
transfected with Arrest-IN reagent (Open Biosystems) in a 6:1 ratio
with DNA (ml/mg) using 2–5mg of plasmid DNA.
Immunoprecipitation and western blotting
Transfected cells were gently washed 2 in phosphate-buffered
saline and then lysed using 1.0 ml 1% NP-40 lysis buffer (1% NP-40,
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, Complete Protease Inhibitor
tablet, EDTA-free (Roche, Indianapolis, IN), 1mM sodium orthovana-
date, 1 mM sodium fluoride, and 0.1% b-mercaptoethanol) per T-75
flask for 20 minutes on ice. Lysed cells were scraped and transferred
into a 1.5 ml microcentrifuge tube. Extracts were centrifuged for
10 minutes at 14,000 r.p.m. at 4 1C. Then, 800ml of supernatant was
immunoprecipitated overnight using 20ml of anti-FLAG (M2) beads
(Sigma-Aldrich, St Louis, MO) or 10ml of anti-myc antibody with
30ml of 50% slurry of Protein-A/G Sepharose beads (1 phosphate-
buffered saline). The immunoprecipitates were washed and subjected
to SDS-PAGE and western blotting as previously described
(Palavalli et al., 2009). Primary antibodies used in our signal
transduction pathway analysis were anti-MAP3K5 (3762), anti-P-
MAP3K5 (S83; 3761), anti-P-MAP3K5 (S967; 3764), anti-P-ERK1/2
(T202/Y204; 9101), anti-ERK1/2 (9102), anti-P-MEK1/2 (S217/221;
9121), anti-MEK1/2 (9122), anti-P-p38 (T180/Y182; 9211), anti-p38
(9212), anti-P-MKK4 (T261; 9151), anti-MKK4 (9152), anti-Trx
(2429; Cell Signaling, Danvers, MA), anti-myc (SC-40; Santa Cruz
Biotechnology, Dallas, TX), and anti-GAPDH (CB1001; Calbiochem-
EMD Biosciences, Billerica, MA).
Pooled stable expression
To make lentivirus, MAP3K5 constructs were cotransfected into
HEK293T cells seeded at 1.5 106 per T75 flask with pVSV-G and
pFIV-34N (kind gifts from Todd Waldman, Georgetown University,
Washington , DC) helper plasmids using Arrest-IN as described by the
manufacturer. Virus-containing media were harvested 60 hours after
transfection, filtered, aliquoted, and stored at  80 1C. Mel-STR cells
(kind gift from Dr Robert Weinberg, Whitehead Institute, Cambridge,
MA) were grown in RPMI-1640 (Lonza, Walkersville, MD) and
supplemented with 10% FBS (HyClone, Logan, UT). The 2183
(17T) cells were maintained in RPMI-1640 and supplemented with
10% FBS. Cells were seeded at 1.5 106 cells per T75 flask 24 hours
before infection. Lentivirus for MAP3K5 (wild type or R256C point
mutant) and empty vector control were used to infect both Mel-STR
and A375 cells as previously described (Prickett et al., 2009). Stable
expression of MAP3K5 proteins (wild type and mutant) was
determined by immunoprecipitation and SDS-PAGE analysis
followed by immunoblotting with anti-MAP3K5 and anti-GAPDH to
show equivalent expression among pools.
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Figure 4. Somatic mutation in mitogen-activated protein kinase kinase
kinase-5 (MAP3K5) at residue R256C causes increased binding of thioredoxin
(TXN/Trx). MAP3K5 binds Trx in the absence of stimuli and mutation
enhances binding. (a) HEK293 cells transiently transfected with MAP3K5-FLAG
(wild type (WT), R256C, or vector (vec)) and myc-Trx were analyzed for
MAP3K5/Trx complex formation by co-immunoprecipitation with anti-myc.
(b) 2183 melanoma stable pooled clones expressing MAP3K5-FLAG (WT,
R256C, or empty vector) were analyzed for MAP3K5/Trx complex formation
by co-immunoprecipitation with anti-Trx. Immunoprecipitates were analyzed
using the antibodies shown and lysates were probed with anti-GAPDH as an
internal control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IP,
immunoprecipitation.
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Proliferation assays
To examine growth potential, pooled clones were seeded into 96-
well plates at 300 cells per well in 1, 2.5, or 10% serum-containing
medium and incubated for 13–17 days. Samples were analyzed every
48 hours by lysing cells in 50ml 0.2% SDS per well and incubating for
2 hours at 37 1C before addition of 150ml/well of SYBR Green I
solution (1:750 SYBR Green I (Invitrogen-Molecular Probes, Carlsbad,
CA) diluted in distilled H2O). Plates were analyzed using a BMG
Labtech FLOUstar Optima (Cary, NC).
Soft agar assay
Stable pooled MAP3K5 clones were plated in triplicate at 1,000 cells
per well and in top plugs consisting of sterile 0.33% Bacto-Agar (BD,
Sparks, MD) and 10% FBS (HyClone) in a 24-well plate. The lower
plug contained sterile 0.5% Bacto-Agar and 10% FBS. After 2 weeks,
the colonies were photographed and quantitated using ImageJ (NIH
software, NIH, Bethesda, MD).
Lentiviral shRNA
Constructs for stable depletion of MAP3K5 (cat no. RHS4533-
NM_005923) were obtained from Open Biosystems and were
confirmed to efficiently knockdown MAP3K5 at the protein level.
Lentiviral stocks were prepared as previously described (Prickett et al.,
2009). Melanoma cell lines (24T, 32T, Mel-Juso, 12T, 501Mel, and
A375) were infected with shRNA lentiviruses for each condition
(vector and two different MAP3K5-specific shRNAs). Selection of
stable pooled clones was done in the presence of 3mg ml 1
puromycin containing normal medium for 3–5 days before determin-
ing knockdown efficiency. Stably infected pooled clones were tested
in functional assays.
Reverse transcription–PCR
Total RNA was extracted from pooled clones stably knocked
down for endogenous MAP3K5 following the manufacturer’s protocol
for the RNeasy Mini Kit (QIAGEN 74101, Frederick, MD). Total RNA
was eluted in 30ml diethylpyrocarbonate-treated distilled H2O. A
total of 1mg of total RNA was used for single-strand complementary
DNA synthesis using a SuperScript III First-Strand kit (Invitrogen Life
Technologies, 18080-051). Complementary DNA was amplified
using the oligo dT20 (Invirtogen-Life Technologies) primer supplied
in the kit. To test for loss of MAP3K5 message, we used 1ml of
complementary DNA in the PCR reaction with either MAP3K5
primers or GAPDH primers (Supplementary Table S4 online).
Proliferation assays of stable knockdown cells
To examine growth potential, stably depleted clones were seeded into
96-well plates at 500 cells per well in 1, 2.5, or 10% serum-
containing medium and incubated for 6–8 days. Samples were
analyzed every 2–3 days by lysing cells in 50ml 0.2% SDS per well
and incubating for 2 hours at 37 1C before addition of 150ml per well
of SYBR Green I solution (1:750 SYBR Green I (Invitrogen-Molecular
Probes) diluted in distilled H2O). Plates were analyzed using a BMG
Labtech FLOUstar Optima.
Data access
All somatic variants found in MAP3K5 present in our melanoma
cohorts will be deposited to dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/).
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